Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adverse Event Analysis Could Leap Forward With New Statistical Techniques

Executive Summary

Data mining the FDA Adverse Event Reporting System could take a leap forward as researchers validate a new statistical algorithm and publish results later this year

You may also be interested in...



AERS Overhaul Will Be Overseen By FDA’s New Bioinformatics Board

FDA's initiative to develop an advanced Adverse Event Reporting System that has the ability to analyze data and assist medical reviewers in their efforts to spot safety signals will be overseen by a new Bioinformatics Board

AERS Overhaul Will Be Overseen By FDA’s New Bioinformatics Board

FDA's initiative to develop an advanced Adverse Event Reporting System that has the ability to analyze data and assist medical reviewers in their efforts to spot safety signals will be overseen by a new Bioinformatics Board

J&J Risperdal Pituitary Tumor Risk To Be Evaluated In FDA Claims Study

FDA's Division of Psychiatry Products and Office of Surveillance & Epidemiology are planning a study to determine if Johnson & Johnson's Risperdal (risperidone) has an increased risk of pituitary adenoma versus other antipsychotics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel